{
  "guideline": {
    "id": "PA166328688",
    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Fluorouracil - DPYD",
    "objCls": "PGx Association",
    "source": "FDA",
    "version": 0,
    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328688",
    "relatedChemicals": [
      {
        "id": "PA128406956",
        "name": "fluorouracil",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA145",
        "name": "dihydropyrimidine dehydrogenase",
        "symbol": "DPYD"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166310702",
      "name": "Recommendation Annotation PA166310702",
      "population": "Affected subgroup: DPYD intermediate or poor metabolizer",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA128406956",
          "name": "fluorouracil",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452213141,
        "html": "<p>&quot;Results in higher adverse reaction risk (severe, life-threatening, or fatal toxicities). No dosage has proven safe in poor metabolizers and insufficient data are available to recommend a dosage in intermediate metabolizers. Withhold or discontinue in the presence of early-onset or unusually severe toxicity.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "DPYD": "0.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166310704",
      "name": "Recommendation Annotation PA166310704",
      "population": "Affected subgroup: DPYD intermediate or poor metabolizer",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA128406956",
          "name": "fluorouracil",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452213143,
        "html": "<p>&quot;Results in higher adverse reaction risk (severe, life-threatening, or fatal toxicities). No dosage has proven safe in poor metabolizers and insufficient data are available to recommend a dosage in intermediate metabolizers. Withhold or discontinue in the presence of early-onset or unusually severe toxicity.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "DPYD": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166310703",
      "name": "Recommendation Annotation PA166310703",
      "population": "Affected subgroup: DPYD intermediate or poor metabolizer",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA128406956",
          "name": "fluorouracil",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452213142,
        "html": "<p>&quot;Results in higher adverse reaction risk (severe, life-threatening, or fatal toxicities). No dosage has proven safe in poor metabolizers and insufficient data are available to recommend a dosage in intermediate metabolizers. Withhold or discontinue in the presence of early-onset or unusually severe toxicity.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "DPYD": "0.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166310741",
      "name": "Recommendation Annotation PA166310741",
      "population": "Affected subgroup: DPYD intermediate or poor metabolizer",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA128406956",
          "name": "fluorouracil",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452213180,
        "html": "<p>&quot;Results in higher adverse reaction risk (severe, life-threatening, or fatal toxicities). No dosage has proven safe in poor metabolizers and insufficient data are available to recommend a dosage in intermediate metabolizers. Withhold or discontinue in the presence of early-onset or unusually severe toxicity.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "DPYD": "1.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [],
  "version": "2024-03-08-14-34"
}